Skip to main content

Table 2 Mean (95% CI) 25-OHD and percent reaching 75 nmol/L (N = 65)

From: A randomized controlled trial of vitamin D dosing strategies after acute hip fracture: No advantage of loading doses over daily supplementation

  Placebo 50,000 100,000 p-value
Baseline (n = 59)     
Mean 25-OHD, unadjusted     
   serum collection at -3 to 0 days, n = 34 58.7 (43.4-74.0)
n = 7
52.3 (37.4-67.2)
n = 14
44.3 (30.8-57.8)
n = 13
0.39
   serum collection at days 1-3, n = 25 41.6 (29.3-53.9)
n = 11
59.0 (28.4-89.6)
n = 6
76.0 (49.1-102.8)
n = 8
0.03
Mean 25-OHD, adjusted for time to measure, n = 59 46.7 (34.8-58.6)
n = 18)
53.5 (42.3-64.8)
n = 20
58.4 (47.3-69.5)
n = 21
0.37
4-week (n = 50)     
Mean 25-OHD, unadjusted 69.8 (59.8-79.8)
n = 17
84.1 (69.3-98.9)
n = 17
75.6 (67.6-83.6)
n = 16
0.17
Mean 25-OHD, adjusted for time to measure* 69.3 (58.4-80.2)
n = 17
84.5 (73.7-95.3)
n = 17
75.6 (64.5-86.8)
n = 16
0.15
Proportion ≥ 75 nmol/L 47.1% 58.8% 50.0% 0.76
3-month (n = 47)     
Unadjusted 85.0 (73.6-93.3)
n = 17
85.2 (74.5-95.9)
n = 12
74.3 (66.1-82.5)
n = 18
0.17
Mean 25-OHD, adjusted for time to measure** 86.7 (77.6-95.9)
n = 17
84.2 (73.6-94.9)
n = 12
73.3 (64.5-82.1)
n = 18
0.09
Proportion ≥ 75 nmol/L 76.5% 75% 44.4% 0.09
  1. Baseline data (n = 59) was missing for two participants, and four outliers with 25-OHD taken at 6, 10 or 12 days were not included. 4-week data (n = 50) was missing for 13 participants, and two outliers with 25-OHD taken at <13 days were not included. 3-month data (n = 47) was missing for 18 participants. Significant difference between 100,000 and placebo (post-hoc). Mean time between bolus vitamin D dose and baseline 25-OHD measure was 0.36 days. *Mean time between bolus vitamin D dose and 25-OHD at second measure was 28.1 days. **Mean time between bolus vitamin D dose and 25-OHD at third measure was 98.9 days.